and TARRYTOWN, N.Y., March 16, 2020 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc today announced they have started a clinical program evaluating Kevzara® (sarilumab) in patients ...

Yancopoulos, M.D., Ph.D., Regeneron Co-Founder, President and Chief Scientific Officer. "Emerging evidence with Kevzara and other repurposed drugs in the COVID-19 crisis highlight the challenges ...

Sanofi and Regeneron just added another building block to a nascent immunology franchise expected to bring in $5 billion or more by 2022. But to get there, their new Kevzara will have to go up ...

Sanofi SNY and its collaboration partner, Regeneron Pharmaceuticals REGN intend to restructure their antibody collaboration into a royalty-based agreement for Kevzara (sarilumab) and Praluent ...

With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...

Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara ® (sarilumab ...

Sarilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. KEVZARA ® (sarilumab) is an injectable prescription medicine called an interleukin-6 (IL-6 ...

A day earlier, Regeneron (ticker: REGN) said it had started trials with its existing arthritis drug, Kevzara, which might prove useful in treating lung inflammation in Covid-19 patients ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara. While Sanofi records sales, Regeneron registers its share of profits/losses in connection with the global ...

TARRYTOWN, N.Y. and PARIS, July 2, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Phase 3 trial of Kevzara® (sarilumab ...